Celldex Therapeutics Files 8-K on Financials
Ticker: CLDX · Form: 8-K · Filed: Nov 6, 2024 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations
TL;DR
Celldex dropped an 8-K on Nov 6th covering financials. Check it out.
AI Summary
Celldex Therapeutics, Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company was formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC.
Why It Matters
This 8-K filing provides crucial updates on Celldex Therapeutics' financial performance and operational status, which is important for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Registrant
- AVANT IMMUNOTHERAPEUTICS INC (company) — Former company name
- T CELL SCIENCES INC (company) — Former company name
- November 6, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Celldex Therapeutics, Inc.'s results of operations and financial condition.
When was this 8-K filed?
This 8-K was filed on November 6, 2024.
What were Celldex Therapeutics' previous names?
Celldex Therapeutics, Inc. was formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC.
Where is Celldex Therapeutics, Inc. located?
Celldex Therapeutics, Inc. is located at Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827.
What is the Standard Industrial Classification code for Celldex Therapeutics, Inc.?
The Standard Industrial Classification code for Celldex Therapeutics, Inc. is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-11-06 16:01:33
Filing Documents
- f8k_110624.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 54KB
- 0001171843-24-006056.txt ( ) — 272KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_110624_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter of 2024. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release of Celldex Therapeutics, Inc., dated November 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Celldex Therapeutics, Inc. Date: November 6, 2024 By: /s/ Sam Martin Sam Martin Senior Vice President and Chief Financial Officer